id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S4995 R13092 |
Drechsel, 2020 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.59 [0.06;41.24] C | 0/14 1/66 | 1 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4997 R13103 |
Fu - Etanercept, 2019 | Congenital malformations (majors) | 1st trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation | 0.79 [0.05;12.80] C | 1/85 1/67 | 2 | 85 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3123 R4860 |
De Lima, 2018 | Major congenital abnormalities | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.79 [0.01;43.11] C | 0/15 0/12 | 0 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4098 R8746 |
Carman - Etanercept (Controls unexposed, disease free), 2017 | Major malformations | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No |
0.95 [0.49;1.85] C excluded (control group) |
11/210 59/1,078 | 70 | 210 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4099 R8761 |
Carman - Etanercept (Controls unexposed, sick), 2017 | Major malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort (claims database) | unexposed, sick | Adjustment: No |
1.08 [0.57;2.05] C excluded (exposition period) |
11/210 94/1,932 | 105 | 210 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4106 R8796 |
Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 | Major birth defects among all pregnancies | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 0.91 [0.37;2.23] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3009 R4305 |
Hoxha, 2017 | Congenital malformation | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.43 [0.02;7.66] C | 1/24 1/11 | 2 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3194 R5156 |
Bröms a (Controls unexposed, disease free), 2016 | Any major birth defect | 3 months or more before pregnancy or1st trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
1.53 [1.12;2.08] C excluded (control group) |
43/683 52,592/1,250,192 | 52,635 | 683 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3193 R5134 |
Bröms a (Controls unexposed, sick), 2016 | Any major birth defect | 3 months or more before pregnancy or1st trimester excluded | population based cohort retrospective | unexposed, sick | Adjustment: Yes |
1.32 [0.93;1.82] excluded (exposition period) |
43/683 1,019/21,549 | 1,062 | 683 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3069 R4684 |
Agosti, 2015 | Major malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, sick | Adjustment: No |
3.13 [0.12;81.01] C excluded (exposition period) |
1/24 0/24 | 1 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4104 R8792 |
Chambers - Etanercept, 2015 | Major birth defects in live born infants | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 2.77 [1.04;7.35] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2888 R4105 |
Weber-Schoendorfer, 2015 | Major birth defects | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: Yes | 2.20 [1.01;4.80] | 21/421 21/1,385 | 42 | 421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4074 R8624 |
Cooper, 2014 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 1.59 [0.30;8.47] | 2/56 4/171 | 6 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2897 R4080 |
Diav-Citrin (Controls exposed to other treatments), 2014 | Major malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.72 [0.16;3.12] C excluded (control group) |
3/65 5/79 | 8 | 65 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2893 R4066 |
Diav-Citrin (Controls unexposed, disease free), 2014 | Major malformations | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 1.98 [0.51;7.69] C | 3/65 8/336 | 11 | 65 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3014 R4502 |
Casanova, 2013 | Congenital malformations (NOS) | 3 months (or more) before pregnancy or during pregnancy excluded | retrospective cohort | exposed to other treatment, sick | Adjustment: No |
4.58 [0.28;74.22] C excluded (exposition period) |
1/60 1/271 | 2 | 60 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13730 R53469 |
Viktil (Controls exposed to other treatments), 2012 | Major malformations | 3 months or more before pregnancy or1st trimester | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.34 [0.02;5.67] C excluded (control group) |
0/40 50/1,421 | 50 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13731 R53471 |
Viktil (Controls unexposed, NOS), 2012 | Major malformations | 3 months or more before pregnancy or1st trimester excluded | population based cohort propective | unexposed (general population or NOS) | Adjustment: No |
0.38 [0.02;6.18] C excluded (exposition period) |
0/40 5,000/154,976 | 5,000 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 9 studies | 1.67 [1.08;2.58] | 64 | 680 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick, ADA only; 2: Controls unexposed, disease free;
Asymetry test p-value = 0.2775 (by Egger's regression)
slope=0.8653 (0.3424); intercept=-0.6031 (0.5123); t=1.1774; p=0.2775
excluded 13730, 2897, 3194, 4098